Aardvark Therapeutics (NASDAQ:AARD) Raised to “Hold” at Wall Street Zen

Aardvark Therapeutics (NASDAQ:AARD) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Friday.

AARD has been the subject of a number of other reports. Bank of America upped their price target on shares of Aardvark Therapeutics from $22.00 to $26.00 and gave the company a “buy” rating in a report on Thursday, March 27th. Royal Bank of Canada lowered their price target on shares of Aardvark Therapeutics from $21.00 to $20.00 and set an “outperform” rating for the company in a report on Thursday, May 15th. Cantor Fitzgerald reiterated an “overweight” rating and set a $50.00 price target on shares of Aardvark Therapeutics in a report on Tuesday, April 1st. Finally, Morgan Stanley started coverage on shares of Aardvark Therapeutics in a report on Monday, March 10th. They set an “overweight” rating and a $29.00 price target for the company. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $31.25.

Aardvark Therapeutics Price Performance

Shares of AARD stock opened at $11.81 on Friday. Aardvark Therapeutics has a one year low of $4.88 and a one year high of $19.58. The firm has a 50-day moving average price of $9.52.

Aardvark Therapeutics (NASDAQ:AARD) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($0.71) EPS for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.01).

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in AARD. Decheng Capital LLC bought a new position in Aardvark Therapeutics in the 1st quarter worth $29,419,000. Walleye Capital LLC bought a new position in Aardvark Therapeutics in the 1st quarter worth $88,000. Braidwell LP bought a new position in Aardvark Therapeutics in the 1st quarter worth $3,755,000. Adage Capital Partners GP L.L.C. bought a new position in Aardvark Therapeutics in the 1st quarter worth $1,878,000. Finally, Cormorant Asset Management LP bought a new position in Aardvark Therapeutics in the 1st quarter worth $6,009,000.

About Aardvark Therapeutics

Aardvark Therapeutics, Inc operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.